Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Five-year project seeks new weapons against drug-resistant bacteria

Lethal lettuce in Missouri. Murderous onions in Colorado. To biochemists at the University of Oklahoma, these aren't just headlines – they're warnings of the risks posed by drug-resistant bacteria and the human cost of inaction. Treatment of chronic conditions

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Lethal lettuce in Missouri. Murderous onions in Colorado. To biochemists at the University of Oklahoma, these aren't just headlines – they're warnings of the risks posed by drug-resistant bacteria and the human cost of inaction.

Treatment of chronic conditions and many surgeries requires antibiotics. When bacteria become resistant to antibiotics and other drugs, many of our medical advances will also fail." Helen Zgurskaya, George Lynn Cross Research Professor, OU Department of Chemistry and Biochemistry

Zgurskaya and Valentin Rybenkov, an OU professor of biochemistry, are leading a five-year, $5.3 million project funded by the National Institute of Allergy and Infectious Diseases to ensure that doesn't happen. They aim to find new ways to deliver lifesaving drugs directly into resistant pathogens.

The work is essential. Without new medicines, experts predict that drug-resistant bacteria could kill as many as 2 million people annually by 2050.

"We usually live together with bacteria; we depend on them for gut health and immunity," Rybenkov said. "We also have ways to defend against harmful bacteria, if necessary. But occasionally our defenses fail. When this happens and they grow faster than they're killed by our immune system, we need antibiotics."

Unfortunately, bacterial resistance to the most common antibiotics is increasing rapidly worldwide. In October 2025, the World Health Organization reported that antibiotic resistance has been growing by as much as 15% annually, and that as many as 1 in 6 bacterial infections are resistant. In Southeast Asia and the eastern Mediterranean, it's closer to 1 in 3.

In the search for remedies, Zgurskaya and Rybenkov have zeroed in on a class of pathogenic germs called gram-negative bacteria (GNB), which have evolved elaborate methods to protect their cell interiors from intruders, including antibiotics.

Unlike gram-positive bacteria, which possess one cell membrane, GNB have two membranes, including a robust outer wall. Resistant bacteria also possess a stronger "efflux" mechanism – protein pumps designed to purge toxic substances from the cell's interior. These defenses make it difficult for current classes of drugs to do their work.

To find holes in GNB defenses, Zgurskaya and Rybenkov are testing the permeation properties of about 2,000 chemicals and compounds against hundreds of efflux pump variants to identify candidates that could slip through the membranes of drug-resistant pathogens, including P. aeruginosa, E. coli, K. pneumoniae and A. baumannii. Once an initial atlas of viable compounds is created, the researchers plan to expand their work to study even more chemicals.

They're also studying how protein pumps work at the molecular level in a bid to identify new avoidance strategies.

"Think of a boat with a tiny hole," Zgurskaya said. "Without intervention it will sink, slowly but surely. But if the boat has a water pump, it removes whatever accumulates. It's a similar mechanism in gram-negative bacteria. Our job, as researchers, is to find a way to create a hole and turn off the pump."

With the help of machine learning, laboratory results will be tested against an even bigger library of chemicals – "hundreds of thousands," Zgurskaya said – to look for patterns and relationships that might point to new, more effective therapeutics.

"There is no easy way to predict what kind of molecule can get through a cell membrane," Rybenkov said. "Artificial intelligence helps us navigate the data."

Overuse of antibiotics is often cited as the leading cause of bacterial resistance, but that's only part of the story, Rybenkov said. "Bacteria want to spread; it's a natural process," he said. "We depend on bacteria for our way of life, but some bacteria don't like us. To them, we're just food."

The OU researchers are collaborating on the project with Paolo Ruggerone, a professor in the Department of Physics at the University of Cagliari, Italy; John Walker, an associate professor of pharmacology and physiology at Saint Louis University; and ArrePath, a drug-discovery firm based in Princeton, New Jersey.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
02How will this discovery change cancer science?

This is a win for the field. Until now, we have been focused on immune therapies that might make tumors more vulnerable to the body's immune system, and on finding new chemotherapy combinations that kill cancer cells. This new treatment has given us a new focus, and I think it will spur a lot of scientific discovery over the next few years. There have only been a handful of KRAS researchers and their relevance to therapy was always questioned. That is about to change. The most important next step for the field is to better understand the biology of cancer. We know that many pancreatic tumors will eventually become resistant to daraxonrasib, and we need to understand how this happens. We also need to identify additional genetic pathways and treatments that can target them. That's how we will turn pancreas cancer from a deadly, deadly cancer into something we can manage-and one day, even cure.

Source: www.news-medical.net ↗
03You have worked across the full drug development pipeline. How has that experience shaped your view of where AI can have the greatest impact in drug safety discovery?

Having worked across different parts of the discovery process, I think broad exposure changes the way you think. I have developed quantum chemistry, artificial intelligence (AI) and machine learning (ML) methods in research settings, but I have also had the chance to apply them in real discovery environments for materials and pharmaceuticals. That experience has shown me how different parts of the discovery pipeline interact, what their motivations are, and how they communicate. AI and ML have been used in early discovery for many years, but the biggest recent shift is in areas dominated by human processes and communication. Computers can now interact directly with human language and analytical images, opening new applications such as AI research assistants and AI-assisted dossier drafting. That means AI can start to work more collaboratively with scientists, although expert oversight and guardrails remain essential. In nonclinical safety, I think the biggest impact will be AI working alongside safety scientists to unearth key data, connect safety science with earlier discovery and later clinical work, and help process, predict, and summarize important outcomes. That could help safety science integrate more tightly with design, make, and test cycles in discovery, while also interfacing earlier with clinical science. Save a Copy of This Exclusive Interview by Downloading the Free PDF

Source: www.news-medical.net ↗
04Can you please give an overview of BenevolentBio?

What we're trying to do here at Benevolent is develop systems and processes that allow us to tap into the huge amount of public information and some propriety databases that we have paid to access and through that, generate hypotheses which our scientists can then triage. We've got over ten times the amount of information in our database at present (and it’s growing) than we believe that companies such as Watson have. Bringing that and filtering the signals from the ‘noise’ to our experienced drug discovery chemists and biologists, means, firstly, we can reduce the amount of time we take to triage new hypotheses, and secondly, we can develop more predictive chemical tools to allow us to make better molecules and also to reposition existing molecules for new indication.

Source: www.news-medical.net ↗
05What are carbs?

Your weight loss plan should keep you healthy and strong as you lose the extra weight. Many plans include a diet low in carbohydrates. Carb cycling is a method of optimizing your carbohydrate intake to meet your needs while dieting, fasting, and working out. When you're carb cycling, you consume carbs to meet your needs on some days and avoid them on other days. The aim of carb cycling is to consume carbohydrates when your body needs them and exclude them at other times. Such strategies in your diet plan can help your weight loss efforts. Carbohydrates, or carbs, are a significant part of the average human diet. Along with proteins and fats, they make up the bulk of your daily meals. Most carbohydrates are broken down by your body into glucose to provide energy for your cells and tissues. Carbohydrates in your diet are of three types — sugars, starches, and fiber. Sugars are simple carbs. Glucose, sugar (sucrose), lactose found in milk, and fructose found in fruits, are naturally occurring sugars. Your body metabolizes these molecules rapidly to yield energy. Starches are complex carbs. They're large molecules that consist of hundreds of molecules of simple sugars joined together. Your body needs to break them down to release energy. Starches are found in bread, potatoes, peas, corn, cereals, and pasta. Fiber is also a complex carbohydrate. Human bodies can't break down these large molecules, so they provide no energy. They're usually excreted as they are in the feces. They add bulk to your meal, so you feel full. Fiber in the diet helps avoid constipation and lowers blood sugar and cholesterol levels. Carbohydrates are an essential part of your diet. A typical diet provides 45% to 65% of its calories from carbohydrates. If you have 2,000 calories a day, you should have about 275 grams of carbohydrates. Always try to choose healthy foods for your carb intake:

Source: www.medicinenet.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →